Women's Health Therapeutics Market Trends, Industry | 2031
Women's Health Therapeutics Market Trends, Industry | 2031
Segments - Women’s Health Therapeutics Market by Types (Infection, Pregnancy, and Oncology [Cervical Cancer, Vaginal & Vulvar Cancer, Uterine Cancer, and Ovarian Cancer]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-996
| 4.2 Rating
| 82 Reviews
| 164 Pages
| Format :
Report Description
Women’s Health Therapeutics Market Outlook 2031
The global women’s health therapeutics market size was valued at USD 179.14 Billion in 2022 and is projected to reach USD 382.69 Billion by 2031, expanding at a substantial CAGR of 8.8.% during the forecast period, 2023–2031. The growth of the market is attributed to the growing prevalence of chronic disease, increasing expenditure on healthcare, lifestyle-associated disorders, launch of novel and effective drugs, and complications related to pregnancy.
In healthcare sector, women health therapeutics market is leading because every woman deals with some type of gynecological disorder at some point in her entire life. Women’s health therapeutics comprises of extensive range of treatment by using several devices and drugs for different health disorders in women.
Various advanced technologies are present for the treatment of women’s health disorders includes ovarian-related problems, cancer, and urological disorders. Many gynecological diseases are cured with proper treatment but in some cases, they can be fatal if diagnosed at right time. Currently, there is pipeline of molecules such as AZD4901, romosozumab (AMG785), abaloparatide, elagolix, ASP1707, vaginorm and teriparatide.
The increasing cases of infertility is projected to push the market. Based on World Health Organization (WHO), infertility in women is serious disability with 5th highest rank across globe, because of this requirement of infertility therapeutics is increasing. According to Centers for Disease Control and Prevention (CDC), around 12% of women have taken any kind of infertility services in their life.
Increasing awareness about cancer, infections, menopause, and osteoporosis is projected to aid the market of women’s health. Furthermore, launch of novel drug therapies by key market players helps for the expansion of the market. In March 2017, TESARO, Inc. received approval for Zejula from the U.S. Food and Drug Administration (FDA). This drug is used for advanced ovarian cancer treatment.
In South Africa, the WHO released guidelines for people living with HIV, to get diagnosis immediately using Antiretroviral Therapy (ART). This recommendation is called as Test and Treat Policy for HIV. Private companies and governments are rising their expenditure on improvement of women’s healthcare particularly for ovarian, cervical, uterine, and breast cancers. Mergers and acquisitions, product approvals, collaborations, and funding are serving the market.
Women’s Health Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of several health conditions and disorders among women is projected to boost the market growth over the forecast period.
- Rising awareness about various drugs treatments among people and increasing production of advanced therapeutic devices are anticipated to drive the market expansion in the coming years.
- Technological advancement is major factor that is expected to drive the expansion of the market.
- Increasing government investments on infrastructure of healthcare and growing adoption of women’s health programs are estimated to fuel the expansion of the market.
- Growing cases of infertility and rising incidences of chronic disorders are expected to push the growth of the market over the forecast period.
- Increasing investment in research and development by major market players is one of the factor responsible for pushing the market growth in the coming years.
- High cost of therapeutic treatment and side effects of drugs are major factor responsible for hampering the market growth over the forecast period.
Scope of Women’s Health Therapeutics Market Report
The report on the global women’s health therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Women’s Health Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Infection, Pregnancy, and Oncology [Cervical Cancer, Vaginal & Vulvar Cancer, Uterine Cancer, and Ovarian Cancer]), |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Bayer AG; Pfizer, Inc.; Teva Pharmaceutical; F. Hoffmann-La Roche Ltd.; Johnson & Johnson Services Inc.; Novartis International AG; Abbott Laboratories; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk A/S; Lupin Pharmaceuticals Inc.; Blairex Laboratories Inc.; and Amgen Inc. |
Women’s Health Therapeutics Market Segment Insights
Type Segment Analysis
Based on types, the women’s health therapeutics market is divided into infection, pregnancy, and oncology. The oncology segment is further sub-divided into cervical cancer, vaginal & vulvar cancer, uterine cancer, and ovarian cancer. The oncology segment is expected to hold a key share of the market during the forecast period.
The cervical cancer is most common type of oncology which held a majority of the revenue share. Novel launch of products, ease reimbursement for better and effective treatment, several product approvals, and rising clinical trials are major factor responsible for propelling the segment growth. In June 2018, the FDA approved Merck and Co. for its KEYTRUDA drug. This drug is used for treating cervical cancer
However, the infection segment is anticipated to expand at a rapid pace during the forecast period due to growing prevalence of tuberculosis (TB), toxoplasmosis, bacterial vaginosis (BV), cytomegalovirus, herpes simplex virus, urinary tract infection (UTI), and hepatitis A, B, C, D, and E. As per Centers for Disease Control and Prevention (CDC), in the U.S., BV is the most dominant infection in women. Also, every year around 21 million women between ages 14 to 49 get affected by BV.
Regional Outlook
On the basis of regions, the women’s health therapeutics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increased funding, growing cases of chronic diseases, and rising mergers and acquisitions.
Based on the Connecticut Small Business Development Center, in 2015, GestVision, Inc., was funded of USD 2 million for diagnostic test of preeclampsia of women who were pregnant. Quest Therapeutics acquired two hospitals, namely, the Hospital of Central Connecticut and the William W. Backus Hospital, of Hartford HealthCare (HHC) in September 2017. This acquisition helped physicians and patients for timely treatment and care by accessing testing services.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising per capita revenue, increasing aging population, growing prevalence of chronic diseases, and increasing product approvals. The China Food and Drug Administration approves Triumeq in January 2018. Triumeq is manufactured by GlaxoSmithKline (GSK). It is single pill and low cost treatment for Human Immunodeficiency Virus (HIV).
Segments
The global women’s health therapeutics market has been segmented on the basis of
Types
- Infection
- Pregnancy
- Oncology
- Cervical Cancer
- Ovarian Cancer
- Uterine Cancer
- Vaginal & Vulvar Cancer
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bayer AG
- Pfizer, Inc.
- Teva Pharmaceutical
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Novartis International AG
- Abbott Laboratories
- Eli Lilly and Company
- Merck & Co., Inc.
- Novo Nordisk A/S
- Lupin Pharmaceuticals Inc.
- Blairex Laboratories Inc.
- Amgen Inc.
Competitive Landscape
Key players competing in the women’s health therapeutics market include Bayer AG; Pfizer, Inc.; Teva Pharmaceutical; F. Hoffmann-La Roche Ltd.; Johnson & Johnson Services Inc.; Novartis International AG; Abbott Laboratories; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk A/S; Lupin Pharmaceuticals Inc.; Blairex Laboratories Inc.; and Amgen Inc.
Major market players are adopting several market strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Women’s Health Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Women’s Health Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Women’s Health Therapeutics Market - Supply Chain
4.5. Global Women’s Health Therapeutics Market Forecast
4.5.1. Women’s Health Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Women’s Health Therapeutics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Women’s Health Therapeutics Market Absolute $ Opportunity
5. Global Women’s Health Therapeutics Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Women’s Health Therapeutics Market Size and Volume Forecast by Types
5.3.1. Infection Pregnancy Oncology
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Women’s Health Therapeutics Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Women’s Health Therapeutics Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Women’s Health Therapeutics Demand Share Forecast, 2019-2026
7. North America Women’s Health Therapeutics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Women’s Health Therapeutics Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Women’s Health Therapeutics Market Size and Volume Forecast by Types
7.4.1. Infection Pregnancy Oncology
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Women’s Health Therapeutics Demand Share Forecast, 2019-2026
8. Latin America Women’s Health Therapeutics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Women’s Health Therapeutics Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Women’s Health Therapeutics Market Size and Volume Forecast by Types
8.4.1. Infection Pregnancy Oncology
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Women’s Health Therapeutics Demand Share Forecast, 2019-2026
9. Europe Women’s Health Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Women’s Health Therapeutics Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Women’s Health Therapeutics Market Size and Volume Forecast by Types
9.4.1. Infection Pregnancy Oncology
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Women’s Health Therapeutics Demand Share Forecast, 2019-2026
10. Asia Pacific Women’s Health Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Women’s Health Therapeutics Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Women’s Health Therapeutics Market Size and Volume Forecast by Types
10.4.1. Infection Pregnancy Oncology
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Women’s Health Therapeutics Demand Share Forecast, 2019-2026
11. Middle East & Africa Women’s Health Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Women’s Health Therapeutics Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Women’s Health Therapeutics Market Size and Volume Forecast by Types
11.4.1. Infection Pregnancy Oncology
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Women’s Health Therapeutics Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Women’s Health Therapeutics Market: Market Share Analysis
12.2. Women’s Health Therapeutics Distributors and Customers
12.3. Women’s Health Therapeutics Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bayer AG Pfizer, Inc. Teva Pharmaceutical F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Novartis International AG Abbott Laboratories Eli Lilly and Company
Methodology
Related Reports
Some other reports from this category!
Our Clients
